The analysis found a dose-dependent increased risk of malignancy with insulin Glargine compared to human insulin12, 66 and also a higher rate for breast cancer in patients receiving insulin Glargine monotherapy relative to those on insulin glargine combined with other insulin preparations12, 67. Here, INS is linked to breast cancer.